Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB119 in Primary Membranous Nephropathy
NCT04652570Phase 2Terminated
- Sponsor
- Tenet Medicines
- Start
- May 2021
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
A Phase 2 trial of vb119 in primary membranous nephropathy (PMN), sponsored by Tenet Medicines. Started May 2021; status: terminated.
02
Drugs
vb119
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT04652570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652570.